ArticleCancer2016
Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.
Article in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 63 citations in OpenAlex.
- Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Trial
- Worse bladder cancer outcomes in women than in men - bias, biology or both?Nature reviews. Urology · 2026Article
- Existing Health Inequities in the Treatment of Advanced and Metastatic Cancers.Current oncology reports · 2024Review
- Sex-related differences in oncological surgery and postoperative outcomes: comprehensive, nationwide study in France.The British journal of surgery · 2024Observational
- Article
- Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.Frontiers in oncology · 2024Article
- Long-term Musculoskeletal Consequences of Chemotherapy in Pediatric Mice.Function (Oxford, England) · 2024Article
- Effects of gender and socio-environmental factors on health-care access in oncology: a comprehensive, nationwide study in France.EClinicalMedicine · 2023Article
- Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions.Oncogenesis · 2023Review
- Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: a population-based study.Journal of orthopaedic surgery and research · 2023Article
- Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.JNCI cancer spectrum · 2023Article
- Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program.Journal of clinical medicine · 2023Article
- MicroRNA-186 suppresses cell proliferation and metastasis in bladder cancer.African health sciences · 2022Article
- Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges-a narrative review.Translational andrology and urology · 2022Review
- circRNA CRIM1 regulates the migration and invasion of bladder cancer by targeting miR182/Foxo3a axis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Prognostic Factors for Bladder Cancer Patients in Malaysia: A Population-Based Study.International journal of environmental research and public health · 2022Article
- Sex-Related Differences in Outcomes for Oropharyngeal Squamous Cell Carcinoma by HPV Status.International journal of otolaryngology · 2022Article
- Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer.Therapeutic advances in medical oncology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWomen with advanced bladder cancer have inferior survival compared with men. However, women treated on clinical trials do not appear to have a survival disadvantage. Less frequent administration of systemic chemotherapy in women with advanced bladder cancer may contribute to their inferior survival.
methodsThe authors identified patients diagnosed with stage IV bladder cancer from 1998 through 2010 using the National Cancer Data Base, a national outcomes database that includes 70% of all newly diagnosed cancer cases in the United States. Sex differences in demographics, systemic chemotherapy administration, and overall survival (OS) were compared.
resultsA total of 23,981 patients were identified (35% of whom were female). Compared with men, women were older, more likely to be black, and less likely to be insured (P<.01 for all). The Charlson-Deyo comorbidity score did not differ between men and women. Women were less likely to receive systemic chemotherapy than men (45% vs 52%; adjusted relative risk, 0.91 [95% confidence interval (95% CI), 0.88-0.94]). Women had a lower median OS compared with men (8.0 months [95% CI, 7.7-8.3 months] vs 9.8 months [95% CI, 9.5-10.0 months]; P<.001). OS remained lower for women on multivariable analysis, even after adjusting for the administration of systemic chemotherapy (hazard ratio for death, 1.11 [95% CI, 1.08-1.15]).
conclusionsWomen are less likely than men to receive systemic chemotherapy for advanced bladder cancer and this difference may partially account for the poorer OS observed in women. However, OS remains lower in women independent of chemotherapy use, and may be related to unmeasured comorbidities, functional status, or tumor biology. Cancer 2016;122:2012-20. © 2016 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.